代谢风险因素与非酒精性脂肪性肝病进展期肝病的系统综述与荟萃分析
该系统综述与荟萃分析纳入22项人群队列研究,评估代谢风险因素对NAFLD患者发生严重肝病事件的预测价值。2型糖尿病与严重肝病风险增加相关(调整HR 2.25),肥胖风险增加较温和(调整HR 1.20),脂质异常和高血压亦独立相关。
要点
- 2型糖尿病使严重肝病事件风险增加逾2倍(调整HR 2.25)。
- 肥胖(BMI>30 kg/m2)与严重肝病风险轻度增加相关(调整HR 1.20)。
- 低HDL、高甘油三酯和高血压亦独立与严重肝病相关。
核心结论
- 2型糖尿病与严重肝病事件风险增加逾2倍相关。
- 肥胖与严重肝病事件风险轻度增加相关。
- 脂质异常和高血压亦独立与严重肝病事件相关。
研究设计与样本
- 系统综述与荟萃分析,纳入22项人群队列研究,其中18项数据可合并。
- 检索MEDLINE、EMBASE、Cochrane Library和ClinicalTrials.gov至2020年1月9日。
- 排除基于临床指征肝活检选择的队列,以更好反映一般人群风险。
- 使用QUIPS工具评估偏倚风险,采用随机效应模型合并风险比。
主要发现
- 低高密度脂蛋白、高甘油三酯和高血压均独立与严重肝病事件相关。
关键数值与推荐
- 严重肝病结局定义为肝硬化、肝硬化并发症或肝脏相关死亡。
- 纳入标准为成人代谢风险因素患者与无代谢风险因素者比较。
临床怎么用
- 利用2型糖尿病和肥胖等代谢风险因素改进高风险人群的病例发现。
- 对NAFLD合并代谢风险因素者进行有效管理以降低肝病负担。
局限性
- 荟萃分析存在显著研究异质性。
- 可能存在小样本阴性研究发表不足。
- 竞争风险可能影响结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide. Many individuals have risk factors associated with NAFLD, but the majority do not develop advanced liver disease: cirrhosis, hepatic decompensation, or hepatocellular carcinoma. Identifying people at high risk of experiencing these complications is important in order to prevent disease progression. This review synthesises the evidence on metabolic risk factors and their potential to predict liver disease outcomes in the general population at risk of NAFLD or with diagnosed NAFLD. METHODS AND FINDINGS: We conducted a systematic review and meta-analysis of population-based cohort studies. Databases (including MEDLINE, EMBASE, the Cochrane Library, and ClinicalTrials.gov) were searched up to 9 January 2020. Studies were included that reported severe liver disease outcomes (defined as liver cirrhosis, complications of cirrhosis, or liver-related death) or advanced fibrosis/non-alcoholic steatohepatitis (NASH) in adult individuals with metabolic risk factors, compared with individuals with no metabolic risk factors. Cohorts selected on the basis of a clinically indicated liver biopsy were excluded to better reflect general population risk. Risk of bias was assessed using the QUIPS tool. The results of similar studies were pooled, and overall estimates of hazard ratio (HR) were obtained using random-effects meta-analyses. Of 7,300 unique citations, 22 studies met the inclusion criteria and were of sufficient quality, with 18 studies contributing data suitable for pooling in 2 random-effects meta-analyses. Type 2 diabetes mellitus (T2DM) was associated with an increased risk of incident severe liver disease events (adjusted HR 2.25, 95% CI 1.83-2.76, p < 0.001, I2 99%). T2DM data were from 12 studies, with 22.8 million individuals followed up for a median of 10 years (IQR 6.4 to 16.9) experiencing 72,792 liver events. Fourteen studies were included in the meta-analysis of obesity (BMI > 30 kg/m2) as a prognostic factor, providing data on 19.3 million individuals followed up for a median of 13.8 years (IQR 9.0 to 19.8) experiencing 49,541 liver events. Obesity was associated with a modest increase in risk of incident severe liver disease outcomes (adjusted HR 1.20, 95% CI 1.12-1.28, p < 0.001, I2 87%). There was also evidence to suggest that lipid abnormalities (low high-density lipoprotein and high triglycerides) and hypertension were both independently associated with incident severe liver disease. Significant study heterogeneity observed in the meta-analyses and possible under-publishing of smaller negative studies are acknowledged to be limitations, as well as the potential effect of competing risks on outcome. CONCLUSIONS: In this review, we observed that T2DM is associated with a greater than 2-fold increase in the risk of developing severe liver disease. As the incidence of diabetes and obesity continue to rise, using these findings to improve case finding for people at high risk of liver disease will allow for effective management to help address the increasing morbidity and mortality from liver disease. TRIAL REGISTRATION: PROSPERO CRD42018115459.
引用
- Jarvis H, Craig D, Barker R, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020. PMID: 32353039. doi:10.1371/journal.pmed.1003100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。